Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Agora Inc (API) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance

Agora Inc
Bio-Rad Laboratories, Inc. Class A Common Stock

Price performance

Price movement over the last 24 hours

Key statistics

Agora Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Agora Inc trades at $4.2 (market cap $355.95M), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $294.72 (market cap $7.94B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 22.3× Agora Inc's market cap. Which is the better fit depends on your goals.

APIBIO
Market Cap
$355.95M$7.94B
Sector
TechnologyHealth
52-Week High
$5.26$339.75
52-Week Low
$3.24$241.71
Enterprise Value
$108.94M$7.75B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Agora Inc

Agora, Inc. (API) trades at $4.22, down 2.54% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 revenue above guidance and its sixth consecutive quarter of GAAP profitability, with net income of $9.53 million in 2025. Recent news highlights management share purchases and a partnership with thymia for real-time health intelligence.

Outlook remains positive with analyst consensus at 60% buy ratings, supported by strong cash flow growth and a low P/B of 0.64. Key risks include competitive pressures in conversational AI and potential volatility from high short interest growth of 30.3% as of March 31, 2026 (Defense World).

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $296.11, down 0.39% today, with a bullish technical outlook supported by moving averages and a consensus price target of $305. The company reported $2.58B revenue in 2025 with net income of $759.90M, showing a significant turnaround from prior losses. Recent news highlights Nasdaq compliance restoration and participation in industry events, reinforcing operational stability.

BIO presents a positive investment case with strong analyst support (53.85% buy ratings) and improving profitability, though high P/E of 49.27 and recent earnings misses pose valuation and execution risks. Upside potential exists if the company meets future earnings expectations, but investors should monitor debt levels and competitive pressures in the biotech sector.

Returns comparison

Trailing returns across standard periods

About Agora Inc

Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.

Read more on API

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO